SCHOTT PHARMA AG & CO. KGAA
SCHOTT PHARMA AG & CO. KGAA/ DE000A3ENQ51 /
1SXP
|
03/09/2024 15:30:42
|
Diferencia
-0.70
|
Volumen |
Bid17:04:00 |
Ask17:04:00 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
34.74EUR
|
-1.98%
|
0
Volumen de negocios: - |
34.48Volumen de oferta: 258 |
34.56Tamaño/ Volumen/ Formato de Ask: 258 |
5.2 mil millonesEUR |
0.43% |
34.16 |
Descripción de negocio
For more than 100 years, the SCHOTT name has represented advanced solutions and services for the global pharmaceutical and biotech industries. With this longstanding expertise, SCHOTT Pharma provides an extensive and scientifically proven product portfolio for the safe storage and administration of injectable drugs to patients all over the world.
SCHOTT Pharma`s portfolio ranges from prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs.
Consejo de gestión & Consejo de supervisión
| CEO |
| - |
| Consejo de gestión |
| Andreas Reisse, Dr. Almuth Steinkuhler |
| Consejo de supervisión |
| Peter Goldschmidt, Dr. Wolfgang Wienand, Ann-Kristin Erkens , Eva Kienle, Christine Wening, Mario Just, Dr. Jorg Flatten, Thomas Schoning, Oliver Spika, Kai Olbricht |
Datos de la empresa
| Nombre: |
SCHOTT PHARMA INH O.N. |
| Dirección: |
Hattenbergstrasse 10,Mainz, 55122 |
| Teléfono: |
- |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.schott-pharma.com/ |
| Industria: |
Healthcare |
| Sector: |
Medical Products |
| Subsector: |
Medical Supplies |
| Fin del año financiero: |
30/09 |
| Acciones de libre circulación: |
23.00% |
| Fecha de OPI: |
28/09/2023 |
Relación con inversores
| Nombre: |
Jasko Terzic |
| IR teléfono: |
- |
| IR-fax: |
- |
| IR e-mail: |
IR.Pharma@schott.com
|
Calendario de la empresa
|
CW 50 | 12/12/2024
Annual Report
|
|
CW 6 | 04/02/2025
General Shareholder Meeting
|
|
CW 7 | 13/02/2025
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 15/05/2025
Interim Report 2nd Quarter/6 Months
|
|
CW 33 | 12/08/2025
Interim Report 3rd Quarter/9 Months
|
